Has Marc Cheng, MD received payments from drug or device companies?

Yes. Drug and device makers reported $417 in general payments to Marc Cheng, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marc Cheng, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marc Cheng, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marc Cheng, MD

Interventional Pain Medicine · Chino, CANPI 1417018342

Payments from drug & device makers

$417in general payments, 2019–2025

Across 33 payments — averaging $12.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$405
Galderma Laboratories, L.p.$12

What the payments were for

Food & beverage$417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	32	$405
Galderma Laboratories, L.p.	1	$12

How this compares

$417 in reported general payments places this provider in the 20th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California →

Medicare billing

Part B allowed, 2024

$347,601

Medicare patients

368

Services billed

3,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	1,994	$39,480
OxycontinOxycodone Hcl	74	$30,822
MovantikNaloxegol Oxalate	45	$20,046
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	691	$16,965
Nucynta ErTapentadol Hcl	14	$14,459
NucyntaTapentadol Hcl	12	$12,190
Lidocaine	111	$11,053
Oxycodone Hcl	617	$8,784
Diclofenac Sodium	69	$8,740
Gabapentin	735	$7,957
Xtampza ErOxycodone Myristate	11	$7,655
Tramadol Hcl	468	$5,980
Fentanyl	68	$5,840
Pregabalin	226	$2,982
Morphine Sulfate ErMorphine Sulfate	98	$2,065

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Chino

Marc LynchChino$114K
Sheldon JordanSanta Monica$3.1M
Ezekiel FinkBeverly Hills$2.3M
Matthew DotyOroville$1.3M
Tim LeierRancho Mirage$749K
Pragya GuptaEscondido$647K
Michael Verdolinla Mesa$563K
Standiford HelmOrange$476K
Patrick BuchananCamarillo$453K
Roy BrownlowSan Diego$452K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →